ストックスクリーナーアプリを入手
8.23
4.44%
0.35
アフターアワーズ：
7.30
-0.93
-11.30%
前日終値:
$7.88
開ける：
$7.97
24時間の取引高:
11,965
Relative Volume:
0.22
時価総額：
$77.31M
収益：
-
当期純損益:
$-129.41M
株価収益率:
-0.3416
EPS:
-24.0922
ネットキャッシュフロー:
$-51.97M
1週間 パフォーマンス:
-2.37%
1か月 パフォーマンス:
-26.91%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$7.8091
$8.23
1週間の範囲:
$7.8091
$9.36
52週間の値動き範囲:
$4.21
$14.21
Leonabio Inc Stock (LONA) Company Profile
名前
Leonabio Inc
セクター
電話
(425) 620-8501
住所
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare LONA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LONA
Leonabio Inc
|
8.23 | 79.38M | 0 | -129.41M | -51.97M | -24.09 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Leonabio Inc Stock (LONA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-26 | 開始されました | Cantor Fitzgerald | Overweight |
| 2026-02-19 | アップグレード | Mizuho | Neutral → Outperform |
| 2024-09-19 | ダウングレード | Mizuho | Outperform → Neutral |
| 2024-09-04 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-09-04 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | ダウングレード | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | 開始されました | Rodman & Renshaw | Buy |
| 2022-10-17 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | 開始されました | Mizuho | Buy |
| 2022-06-23 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | ダウングレード | Jefferies | Buy → Hold |
| 2022-06-23 | ダウングレード | Stifel | Buy → Hold |
| 2022-05-10 | 開始されました | BTIG Research | Buy |
| 2022-04-21 | 開始されました | Berenberg | Buy |
| 2021-12-15 | 開始されました | Goldman | Neutral |
| 2020-10-13 | 開始されました | Goldman | Buy |
| 2020-10-13 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-13 | 開始されました | Jefferies | Buy |
| 2020-10-13 | 開始されました | Stifel | Buy |
すべてを表示
Leonabio Inc (LONA) 最新ニュース
LONA Q1 2026 Earnings: EPS Surprises Above Estimates Amid Pre-Revenue PhaseGuidance Accuracy Score - newsline.com
LONA Q1 2026 Earnings: Narrowed Loss Exceeds Expectations as Cost Discipline ContinuesEarnings Trend Analysis - newsline.com
LeonaBio (LONA) Holds Steady Near Support as Sector Sentiment WeighsLow Beta Factor - newsline.com
LeonaBio names brelgometon as INN for ALS drug candidate ATH-1105 - Investing.com UK
LeonaBio names brelgometon as INN for ALS drug candidate ATH-1105 By Investing.com - Investing.com South Africa
LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit - The Manila Times
LONA Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Progress in Pipeline Despite Market HeadwindsMargin Improvement Report - The Legal Advocate
LeonaBio Inc. (LONA) Q1 2026 Earnings: Surprise EPS Beat Signals Progress Despite Revenue GapEstimate Uncertainty - The Legal Advocate
LeonaBio Gets $20 Price Target Ahead of June Pipeline Test - Bez Kabli
LeonaBio Inc. (LONA) Rises 1.45% as Shares Approach Key Resistance at $10.3Stock News - The Legal Advocate
LONA Initiated Coverage by Piper Sandler -- Rating Set to Overwe - GuruFocus
LeonaBio to Participate in Upcoming Medical and Industry Meetings in June - GlobeNewswire
Piper Sandler initiates LeonaBio stock with overweight rating - Investing.com
Piper Sandler initiates LeonaBio stock with overweight rating By Investing.com - Investing.com Canada
LeonaBio Inc. (LONA) Q1 2026 Earnings: EPS Surprise Provides Bright Spot Amid Revenue Absence and Stock DeclineCash Flow Report - The Legal Advocate
LeonaBio Inc. (LONA) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ReactionOperating Income Trends - The Legal Advocate
LeonaBio Inc. (LONA) Q1 2026 Earnings: Narrower-Than-Expected Loss Buoyed by R&D ProgressEarnings Deceleration Risk - newsline.com
LeonaBio Inc. (LONA) Q1 2026 Earnings: Narrowing Losses Signal Operational DisciplineRetail Earnings Report - Newser
Why Is LeonaBio, Inc. (LONA) Stock Up Today? - Meyka
Why Is LeonaBio, Inc. (LONA) Stock Down Today? - Meyka
ADAR1, Daniel Schneeberger disclose 727,481 shares in LeonaBio (ATHA) - Stock Titan
LeonaBio (ATHA) details 2026 director, auditor and Say-on-Pay votes - Stock Titan
Mizuho Securities Maintains LeonaBio(LONA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Dividend HistoryLeonaBio, Inc. (LONA) - Zacks Investment Research
LONA: LeonaBio, Inc.Insider Transations - Zacks Investment Research
MSN Money - MSN
LeonaBio (LONA) director receives 56,000 stock options at $9.63 strike - Stock Titan
Director at LeonaBio (LONA) granted 56,000 stock options - Stock Titan
Option grant gives LeonaBio (LONA) director 56,000 shares at $9.63 - Stock Titan
Natalie Holles named LeonaBio (LONA) director in initial Form 3 - Stock Titan
LeonaBio (LONA) director Peter B. Silverman files initial Form 3 - Stock Titan
LeonaBio (LONA) director Callori Fred files baseline Form 3 ownership report - Stock Titan
Perceptive Advisors (ATHA) caps LeonaBio stake at 19.99% and gains board seat - Stock Titan
LeonaBio (NASDAQ: ATHA) widens loss as R&D ramps for lasofoxifene and ALS drug - Stock Titan
LeonaBio (NASDAQ: ATHA) widens Q1 loss while funding late-stage trials - Stock Titan
LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
LeonaBio reshapes board with 3 hires as long-serving director exits - Stock Titan
LeonaBio John Fluke Retires, Effective May 4 >LONA - Moomoo
LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D. - Weekly Voice
LeonaBio Enhances Board of Directors with Appointments of - GlobeNewswire
LeonaBio, Inc. (LONA) Stock Forecast 2027, 2031 & 7-Year Price Prediction | Meyka AI - Meyka
How sustainable is LeonaBio (LONA) profit margins? (Selling Pressure) 2026-05-06Hot Market Picks - newser.com
LONA Earnings History & Surprises | EPS & Revenue Results | LEONABIO INC (NASDAQ:LONA) - ChartMill
Leonabio Inc (LONA) 財務データ
収益
当期純利益
現金流量
EPS
Leonabio Inc (LONA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Litton Mark James | PRESIDENT and CEO |
Mar 04 '26 |
Sale |
5.37 |
5,156 |
27,688 |
57,926 |
| Renninger Robert | CHIEF FINANCIAL OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
3,900 |
0 |
16,757 |
| Renninger Robert | CHIEF FINANCIAL OFFICER |
Mar 04 '26 |
Sale |
5.37 |
906 |
4,865 |
15,851 |
| Worthington Mark | GENERAL COUNSEL and CCO |
Mar 03 '26 |
Option Exercise |
0.00 |
5,726 |
0 |
19,704 |
| Worthington Mark | GENERAL COUNSEL and CCO |
Mar 04 '26 |
Sale |
5.37 |
1,328 |
7,131 |
18,376 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
5,856 |
0 |
26,537 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Mar 04 '26 |
Sale |
5.37 |
1,359 |
7,298 |
25,178 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
7,418 |
0 |
17,607 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Mar 04 '26 |
Sale |
5.37 |
1,720 |
9,236 |
15,887 |
2.60%
0.94%
大文字化:
|
ボリューム (24 時間):